Note 15 - Stockholders' Equity (Deficit) (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
	2024		2023
Cost of sales	$	10	$	15
Selling and marketing		72		109
General and administrative		230		300
Research and development		27		57
Total stock-based compensation	$	339	$	481

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended March 31,
	2024			2023
Expected term (in years)		6.00			6.00
Risk-free interest rate		4.23	%		3.41	%
Expected volatility		43.06	%		43.02	%
Expected dividend rate		0	%		0	%

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Shares			Weighted- Average Exercise Price per Share, $		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding – January 1, 2024		981,834		$	19.85		7.58	$	—
Options granted		82,000			0.71		-		—
Options exercised		-			-		-		—
Options forfeited/cancelled		(15,760	)		25.54		-		—
Outstanding – March 31, 2024		1,048,074			18.26		7.52	$	—
Exercisable – March 31, 2024		448,819			33.24		6.20	$	—
Expected to vest – after March 31, 2024		599,255		$	7.05		8.51	$	—

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

	Options Outstanding						Options Exercisable
Exercise Price Range	Number		Weighted average remaining contractual term (years)		Weighted average Exercise Price		Options exercisable		Weighted average remaining contractual term (years)		Weighted average Exercise Price
$0.7051 - $54.60		1,000,031		7.73	$	13.80		401,178		6.56	$	23.97
$63.90 - $119.25		45,774		3.18		99.44		45,372		3.16		99.46
$186.75 - $382.50		1,627		4.74		271.15		1,627		4.74		271.15
$405.00 - $438.75		373		0.91		405.36		373		0.91		405.36
$650.25 - $958.50		269		4.20		727.38		269		4.20		727.38
		1,048,074		7.52	$	18.26		448,819		6.20	$	33.24